The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1 subunit of the cholera toxin (CTA1) a peptide capable of binding to a specific cellular receptor and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit the amino acids corresponding to the amino acid 7 arginine and amino acid 187 cysteine in the native CTA1 have been replaced.
